Ultragenyx Pharmaceutical is a biopharmaceutical company developing treatments for rare genetic diseases across multiple global regions. The company markets four approved biologic therapies targeting conditions including X-linked hypophosphatemia, mucopolysaccharidosis VII, fatty acid oxidation disorders, and familial hypercholesterolemia, while advancing several gene therapy and monoclonal antibody candidates through Phase 2 and Phase 3 clinical trials. The company operates through various research partnerships and collaborations with academic institutions and biotechnology firms.

entry readiness 48 · WEAK SETUP · exit proximity 0

Value area 12.73–26.08 · 49% of 120d volume overhead · moderate overhead